fashion -WSS

fashion

author：Wikipedia 2025-08-26 10:55:48 - browse：387

Stock exchange — Drew Angerer/Getty Images

Sage Therapeutics said Monday that it may need to reduce costs, including through employee layoffs, following the Food and Drug Administration’s denial of its rapid-acting drug for major depressive disorder.

On Friday, the agency granted market clearance for the drug, called Zurzuvae, to treat women with postpartum depression, a smaller commercial market. Sage failed to convince regulators to also approve the drug for depression, a broader condition.

“We don’t agree with the FDA review,” Sage CEO Barry Greene said during an earnings call, a point he made repeatedly. “We are evaluating the [FDA’s response letter] and as soon as we can provide more clarity, we will, on what the next steps are.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Anesthesiologist group: stop taking Ozempic before surgery

leisure time

WSS

In science, is the line between industry and academia shifting?

Unicorn down: Following layoffs, Biofourmis CEO quietly departs

What AAP's gender

How to make Best Hospitals ratings actually useful for patients

Moonlake's readout produced a cash windfall. Risks remain

Complete sequence of Y chromosome published for first time

explore

fashion

Wikipedia

As demand for Covid shots wanes, Moderna seeks its next success

How a symptom of dementia informs our understanding of creativity

23andMe had bad news about my health. I wish a person had delivered it

How to make AI work for medicine

Medical leaders decry Supreme Court decision on affirmative action

Medicare explains how it will choose drugs for negotiation

Hollywood unions extend contract negotiations for actors

Psychedelics group wrestles with new pharma identity

BioMarin wins approval for gene therapy to treat hemophilia A

Hepatitis C has a cure — but many Americans still lack access to it

explore

Medicare explains how it will choose drugs for negotiation

Unicorn down: Following layoffs, Biofourmis CEO quietly departs

Study finds new variant for Parkinson’s in African populations

Neuroscience startup Neumora files for IPO

United colonoscopy coverage change 'may cost lives,' doctors say

AstraZeneca challenges Medicare drug negotiation program

focus

leisure time

knowledge

Wikipedia